抗ARID1A抗体 (Anti-ARID1A Antibody) | ヒト組織免疫染色用抗体
掲載日情報：2019/10/28 現在Webページ番号：10520
ARID1Aに対する抗体(Anti-ARID1A Antibody)です。
高品質なTriple A Polyclonalsブランド抗体となります。
※本製品は研究用です。研究用以外には使用できません。
カートに商品を
追加しました。
追加しました。
特長
- Atlas Antibodies社のポリクローナル抗体は「Atlas Antibodies Advanced Polyclonals」(Triple A Polyclonals)と称され、Atlas Antibodies社企業秘密のソフトウェアにより対象抗原タンパク質に対する最も適した、慎重にデザインされた抗体です。
- アフィニティーリガンドとしてリコンビナント抗原を用いた、Atlas Antibodies社独自の抗原精製過程により、特異性・信頼性・多様性が保持されています。
- 対応するリコンビナント抗原の取り扱いもあり(PrEST抗原)、ウエスタンブロット用のポジティブコントロール、および免疫組織染色での抗体ブロッキングに有用です。
- すべての抗体はHuman Protein Atlas (HPA) プロジェクトにて、様々な正常組織、腫瘍組織で検証されています。
- それぞれの抗体に対して700点以上の免疫組織染色、免疫蛍光染色、ウエスタンブロッティング像が公開されています。
Triple A Polyclonalsとは？
カートに商品を
追加しました。
追加しました。
価格
[在庫・価格 ：2024年04月25日 00時00分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
| 詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Anti-ARID1A, Rabbit-Poly |
|
10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[在庫・価格 ：2024年04月25日 00時00分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
Anti-ARID1A, Rabbit-Poly
文献数： 10
- 商品コード：HPA005456
- メーカー：AAB
- 包装：100μl
- 価格：¥96,000
- 在庫：無(未発注)
- 納期：2週間程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 |
バリデーション情報：STANDARD 別名：B120，BAF250，BAF250a，C10rf4，C1orf4，P270，SMARCF1 Genbank No： 8289 Protein Accession No： O14497 |
||||||
|---|---|---|---|---|---|---|---|
| 別包装品 | 別包装品あり | ||||||
| 法規制等 | |||||||
| 保存条件 | -20℃ | 法規備考 | |||||
| 抗原種 | Human | 免疫動物 | Rabbit | ||||
| 交差性 | Human | 適用 | IC,IHC,Western Blot | ||||
| 標識 | Unlabeled | 性状 | Antigen Affinity Purified | ||||
| 吸収処理 | クラス | IgG | |||||
| クロナリティ | Polyclonal | フォーマット | |||||
| 掲載カタログ |
|
||||||
| 製品記事 |
Atlas Antibodies社文献使用抗体 Atlas Antibodies社における抗体検証の取り組み |
||||||
| 関連記事 | |||||||
カートに商品を
追加しました。
追加しました。
製品情報
免疫組織染色(IHC)  | Immunohistochemical staining of human lymph node shows moderate nuclear positivity in lymphoid cells. 推奨プロトコル(Recommended conditions) |
ウエスタンブロッティング(WB)  | Western blot analysis in control (vector only transfected HEK293T lysate) and aRID1A over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells, LY416884). 推奨プロトコル(Recommended conditions) |
免疫蛍光染色(IF)  | Immunofluorescent staining of human cell line U-251 MG shows localization to nucleoplasm. Antibody staining is shown in green. 推奨プロトコル(Recommended conditions) |
関連データベース(Database Links)
抗原情報(Antigen Sequence)
Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence: : PGLGNVAMGPRQHYPYGGPYDRVRTEPGIGPEGNMSTGAPQPNLMPSNPDSGMYSPSRYPPQQQQQQQQRHDSYGNQFSTQGTPSGSPFPSQQTTMYQQQQQNYK
抗体の精製方法(Purification Method)
Affinity purified using the PrEST antigen as affinity ligand
ホモロジー情報(Interspecies Information)
性状(Form)
40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.
保存方法(Storage)
Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Notes
Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user.
References
Title
Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A
Source
Sci Rep
Shahid M, Gull N, Yeon A, Cho E, Bae J, Yoon HS, You S, Yoon H, Kim M, Berman BP, Kim J.
Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A
Source
Sci Rep
Shahid M, Gull N, Yeon A, Cho E, Bae J, Yoon HS, You S, Yoon H, Kim M, Berman BP, Kim J.
Title
Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer
Source
Virchows Arch
Visser NC, van der Wurff AA, Pijnenborg JM, Massuger LF, Bulten J, Nagtegaal ID.
Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer
Source
Virchows Arch
Visser NC, van der Wurff AA, Pijnenborg JM, Massuger LF, Bulten J, Nagtegaal ID.
Title
Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups
Source
Modern Pathology
Carlos Parra-Herran, Jordan Lerner-Ellis, Bin Xu, Sam Khalouei, Dina Bassiouny, Matthew Cesari, Nadia Ismiil, Sharon Nofech-Mozes.
Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups
Source
Modern Pathology
Carlos Parra-Herran, Jordan Lerner-Ellis, Bin Xu, Sam Khalouei, Dina Bassiouny, Matthew Cesari, Nadia Ismiil, Sharon Nofech-Mozes.
Title
Cancer-Associated Mutations in Endometriosis without Cancer
Source
N Engl J Med
Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM.
Cancer-Associated Mutations in Endometriosis without Cancer
Source
N Engl J Med
Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM.
Title
Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma
Source
Oncotarget
Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, O'Neill R, Solomides C, Peiper SC, Testa JR, Uzzo R, Yang H.
Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma
Source
Oncotarget
Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, O'Neill R, Solomides C, Peiper SC, Testa JR, Uzzo R, Yang H.
Title
Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors
Source
Am J Cancer Res
Nastase A, Teo JY, Heng HL, Ng CC, Myint SS, Rajasegaran V, Loh JL, Lee SY, Ooi LL, Chung AY, Chow PK, Cheow PC, Wan WK, Azhar R, Khoo A, Xiu SX, Alkaff SM, Cutcutache I, Lim JQ, Ong CK, Herlea V, Dima S, Duda DG, Teh BT, Popescu I, Lim TK.
Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors
Source
Am J Cancer Res
Nastase A, Teo JY, Heng HL, Ng CC, Myint SS, Rajasegaran V, Loh JL, Lee SY, Ooi LL, Chung AY, Chow PK, Cheow PC, Wan WK, Azhar R, Khoo A, Xiu SX, Alkaff SM, Cutcutache I, Lim JQ, Ong CK, Herlea V, Dima S, Duda DG, Teh BT, Popescu I, Lim TK.
Title
Systematic in vivo inactivation of chromatin regulating enzymes identifies Setd2 as a potent tumor suppressor in lung adenocarcinoma
Source
Cancer Res
Walter DM, Venancio OS, Buza EL, Tobias JW, Deshpande C, Gudiel AA, Kim-Kiselak C, Cicchini M, Yates TJ, Feldser DM.
Systematic in vivo inactivation of chromatin regulating enzymes identifies Setd2 as a potent tumor suppressor in lung adenocarcinoma
Source
Cancer Res
Walter DM, Venancio OS, Buza EL, Tobias JW, Deshpande C, Gudiel AA, Kim-Kiselak C, Cicchini M, Yates TJ, Feldser DM.
Title
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression
Source
Oncoimmunology
Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression
Source
Oncoimmunology
Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.
Title
Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing – a case report
Source
BMC Cancer
Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes KJ, Wild PJ.
Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing – a case report
Source
BMC Cancer
Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes KJ, Wild PJ.
Title
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma
Source
PLoS One
Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, Liao L, Cho EA, O'Neill R, Solomides C, Peiper SC, Testa JR, Uzzo R, Yang H.
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma
Source
PLoS One
Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, Liao L, Cho EA, O'Neill R, Solomides C, Peiper SC, Testa JR, Uzzo R, Yang H.
Title
Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas
Source
Modern Pathology
Mackenzie Coatham, Xiaodong Li, Anthony N Karnezis, Lien N Hoang, Basile Tessier-Cloutier, Bo Meng, Robert A Soslow, C Blake Gilks, David G Huntsman, Colin J R Stewart, Lynne M Postovit, Martin Köbel, Cheng-Han Lee.
Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas
Source
Modern Pathology
Mackenzie Coatham, Xiaodong Li, Anthony N Karnezis, Lien N Hoang, Basile Tessier-Cloutier, Bo Meng, Robert A Soslow, C Blake Gilks, David G Huntsman, Colin J R Stewart, Lynne M Postovit, Martin Köbel, Cheng-Han Lee.
Title
Molecular genetic heterogeneity in undifferentiated endometrial carcinomas
Source
Mod Pathol
Rosa-Rosa JM, Leskelä S, Cristóbal-Lana E, Santón A, López-García MA, Muñoz G, Pérez-Mies B, Biscuola M, Prat J, Oliva E, Soslow RA, Matias-Guiu X, Palacios J.
Molecular genetic heterogeneity in undifferentiated endometrial carcinomas
Source
Mod Pathol
Rosa-Rosa JM, Leskelä S, Cristóbal-Lana E, Santón A, López-García MA, Muñoz G, Pérez-Mies B, Biscuola M, Prat J, Oliva E, Soslow RA, Matias-Guiu X, Palacios J.
Title
Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment
Source
Oncotarget
Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A.
Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment
Source
Oncotarget
Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A.
Title
Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells
Source
J Biol Chem
Rahmanto YS, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IM.
Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells
Source
J Biol Chem
Rahmanto YS, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IM.
Title
Suppression of the SWI/SNF component Arid1a promotes mammalian regeneration
Source
Cell Stem Cell
Sun X, Chuang JC, Kanchwala M, Wu L, Celen C, Li L, Liang H, Zhang S, Maples T, Nguyen LH, Wang SC, Signer RA, Sorouri M, Nassour I, Liu X, Xu J, Wu M, Zhao Y, Kuo YC, Wang Z, Xing C, Zhu H.
Suppression of the SWI/SNF component Arid1a promotes mammalian regeneration
Source
Cell Stem Cell
Sun X, Chuang JC, Kanchwala M, Wu L, Celen C, Li L, Liang H, Zhang S, Maples T, Nguyen LH, Wang SC, Signer RA, Sorouri M, Nassour I, Liu X, Xu J, Wu M, Zhao Y, Kuo YC, Wang Z, Xing C, Zhu H.
Title
ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance
Source
Hum Pathol
Lee LH, Sadot E, Ivelja S, Vakiani E, Hechtman JF, Sevinsky CJ, Klimstra DS, Ginty F, Shia J.
ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance
Source
Hum Pathol
Lee LH, Sadot E, Ivelja S, Vakiani E, Hechtman JF, Sevinsky CJ, Klimstra DS, Ginty F, Shia J.
Title
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer
Source
Oncotarget
Ibarrola-Villava M, Llorca-Cardeñosa MJ, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S, Navarro S, Ribas G, Cervantes A.
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer
Source
Oncotarget
Ibarrola-Villava M, Llorca-Cardeñosa MJ, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S, Navarro S, Ribas G, Cervantes A.
Title
Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma
Source
Int J Clin Exp Pathol
Abe H, Hayashi A, Kunita A, Sakamoto Y, Hasegawa K, Shibahara J, Kokudo N, Fukayama M.
Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma
Source
Int J Clin Exp Pathol
Abe H, Hayashi A, Kunita A, Sakamoto Y, Hasegawa K, Shibahara J, Kokudo N, Fukayama M.
Title
Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas
Source
PLoS One
Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H.
Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas
Source
PLoS One
Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H.
Title
Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors
Source
J Pathol Clin Res
Ayhan A, Mao T, Suryo Rahmanto Y, Zeppernick F, Ogawa H, Wu R, Wang T, Shih I.
Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors
Source
J Pathol Clin Res
Ayhan A, Mao T, Suryo Rahmanto Y, Zeppernick F, Ogawa H, Wu R, Wang T, Shih I.
Title
Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma
Source
J Exp Clin Cancer Res
He F, Li J, Xu J, Zhang S, Xu Y, Zhao W, Yin Z, Wang X.
Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma
Source
J Exp Clin Cancer Res
He F, Li J, Xu J, Zhang S, Xu Y, Zhao W, Yin Z, Wang X.
Title
Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases
Source
Hum Pathol
Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Cubilla AL, Shih IM, Netto GJ.
Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases
Source
Hum Pathol
Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Cubilla AL, Shih IM, Netto GJ.
Title
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Source
Nature Medicine
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia, David W Speicher, Rugang Zhang.
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Source
Nature Medicine
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia, David W Speicher, Rugang Zhang.
Title
ARID1A expression in gastric adenocarcinoma: Clinicopathological significance and correlation with DNA mismatch repair status
Source
World J Gastroenterol
Inada R, Sekine S, Taniguchi H, Tsuda H, Katai H, Fujiwara T, Kushima R.
ARID1A expression in gastric adenocarcinoma: Clinicopathological significance and correlation with DNA mismatch repair status
Source
World J Gastroenterol
Inada R, Sekine S, Taniguchi H, Tsuda H, Katai H, Fujiwara T, Kushima R.
Title
Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry
Source
F1000Res
Howat W, Miller J, Gounaris I.
Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry
Source
F1000Res
Howat W, Miller J, Gounaris I.
Title
Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynecologic malignancies
Source
J Pathol
Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IM, Wang TL.
Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynecologic malignancies
Source
J Pathol
Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IM, Wang TL.
Title
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
Source
BMC Cancer
Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
Source
BMC Cancer
Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.
Title
Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett’s esophagus
Source
Oncogene
Streppel M, Lata S, DelaBastide M, Montgomery E, Wang J, Canto M, Macgregor-Das A, Pai S, Morsink F, Offerhaus G, Antoniou E, Maitra A, McCombie W.
Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett’s esophagus
Source
Oncogene
Streppel M, Lata S, DelaBastide M, Montgomery E, Wang J, Canto M, Macgregor-Das A, Pai S, Morsink F, Offerhaus G, Antoniou E, Maitra A, McCombie W.
Title
Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma
Source
Modern Pathology
Hsien-Neng Huang, Ming-Chieh Lin, Wen-Chih Huang, Ying-Cheng Chiang, Kuan-Ting Kuo.
Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma
Source
Modern Pathology
Hsien-Neng Huang, Ming-Chieh Lin, Wen-Chih Huang, Ying-Cheng Chiang, Kuan-Ting Kuo.
Title
Loss of ARID1A Expression Correlates with Stages of Tumor Progression in Uterine Endometrioid Carcinoma
Source
Am J Surg Pathol
Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu CH, Wang TL, Shih IM.
Loss of ARID1A Expression Correlates with Stages of Tumor Progression in Uterine Endometrioid Carcinoma
Source
Am J Surg Pathol
Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu CH, Wang TL, Shih IM.
Title
Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma
Source
Int J Gynecol Cancer
Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IM.
Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma
Source
Int J Gynecol Cancer
Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IM.
Title
Functional Analysis of In-frame Indel ARID1A Mutations Reveals New Regulatory Mechanisms of Its Tumor Suppressor Functions
Source
Neoplasia
Guan B, Gao M, Wu CH, Wang TL, Shih IM.
Functional Analysis of In-frame Indel ARID1A Mutations Reveals New Regulatory Mechanisms of Its Tumor Suppressor Functions
Source
Neoplasia
Guan B, Gao M, Wu CH, Wang TL, Shih IM.
Title
Endocervical-type Mucinous Borderline Tumors are Related to Endometrioid Tumors Based on Mutation and Loss of Expression of ARID1A
Source
Int J Gynecol Pathol
Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IM.
Endocervical-type Mucinous Borderline Tumors are Related to Endometrioid Tumors Based on Mutation and Loss of Expression of ARID1A
Source
Int J Gynecol Pathol
Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IM.
Title
Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma
Source
Int J Clin Exp Pathol
Xiao W, Awadallah A, Xin W.
Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma
Source
Int J Clin Exp Pathol
Xiao W, Awadallah A, Xin W.
Title
Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Source
Mod Pathol
Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Source
Mod Pathol
Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
Title
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Source
Virchows Arch
Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Source
Virchows Arch
Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
Title
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation
Source
Cancer Discov
Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine J, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM.
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation
Source
Cancer Discov
Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine J, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM.
Title
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.
Source
Nat Genet
Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY.
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.
Source
Nat Genet
Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY.
Title
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma
Source
Am J Surg Pathol
Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL, Shih IM.
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma
Source
Am J Surg Pathol
Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL, Shih IM.
カートに商品を
追加しました。
追加しました。
抗原情報(Antigen Sequence)
Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence: : PGLGNVAMGPRQHYPYGGPYDRVRTEPGIGPEGNMSTGAPQPNLMPSNPDSGMYSPSRYPPQQQQQQQQRHDSYGNQFSTQGTPSGSPFPSQQTTMYQQQQQNYK[在庫・価格 ：2024年04月25日 00時00分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
| 詳細 | 商品名 |
|
文献数 | ||
|---|---|---|---|---|---|
|
PrEST Antigen ARID1A, Human, Recombinant |
|
0 | |||
[在庫・価格 ：2024年04月25日 00時00分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
PrEST Antigen ARID1A, Human, Recombinant
文献数： 0
- 商品コード：APrEST70748
- メーカー：AAB
- 包装：100μl
- 価格：¥56,000
- 在庫：無(未発注)
- 納期：ご照会下さい ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
カートに商品を
追加しました。
追加しました。
関連製品情報
高性能な免疫組織染色用の抗原賦活化装置： 「Decloaking Chamber NxGen」 ⇒ 詳細はこちら
カートに商品を
追加しました。
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。